Express News | Biofrontera Inc - Data Now Being Analyzed, Interim Results Expected November 2024
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (SBCC)
Express News | Biofrontera Inc. Announces Database Lock of Phase 3 Study of Ameluz®-Photodynamic Therapy (Pdt) in the Treatment of Superficial Basal Cell Carcinoma (Sbcc)
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (Aminolevulinic Acid HCI) Topical Gel, 10% In One Treatment
Express News | FDA Approves Use of up to Three Tubes of Biofrontera Inc.’s Ameluz (Aminolevulinic Acid Hci) Topical Gel, 10% in One Treatment
Express News | Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update